ArticleTherapeutic advances in gastroenterology2025

Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn's disease.

Pauline Wils et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.